Rosebud Biosciences Analysis
What is Rosebud Biosciences?
Rosebud Biosciences develops therapies for rare genetic diseases in children using organoids that replicate genetic mutations. The company focuses on accelerating drug discovery through advanced modeling techniques and partnerships with pharmaceutical companies.
Location
930 Brittan Avenue, San Carlos, California, United States
Employees
1-10
Founded
2020
Product Features & Capabilities
- Organoid platform, targeted therapies for rare genetic diseases, cardiac organoids, hepatic organoids, neural organoids, kidney organoids, drug screening using human induced pluripotent stem cells (hiPSCs), mutation-specific organoid models.
Who are the founders of Rosebud Biosciences
KW
Kitch Wilson
CEO
EL
Evan Lyall
CTO
Business Model
Collaborates with pharma for drug development; funding through grants and investments.
Market Focus
Rosebud Biosciences primarily focuses on the biotechnology industry, specifically developing therapies for rare genetic diseases in children using organoid technology to model human development and replicate genetic mutations.
Investors
- Y Combinator
- National Science Foundation (NSF)
- 10X Capital
- Arvantis Group
- Gaingels
Competitors Overview
Rosebud Biosciences operates in the biotechnology sector, focusing on developing therapies for rare genetic diseases using organoids that replicate genetic mutations. Its main competitors include:
-
Gameto: Specializes in female reproductive longevity and cellular reprogramming, which is a different niche compared to Rosebud's focus on drug screening using organoids.
-
Parallel Bio: Develops immune organoids for disease modeling, overlapping in some therapeutic areas but primarily focused on immunotherapy.
-
HeartBeat.bio: Concentrates on drug discovery for heart failure using cardiac organoids, representing a specific application of organoid technology distinct from Rosebud's broader drug screening approach.
-
Saguaro Biosciences: Creates live cell reagents for AI-supported analysis, which may complement but does not directly compete with Rosebud's drug screening services.
-
NextVivo: Works on organoids for studying autoimmune and infectious diseases, which could be seen as a competitive area but focuses on different disease models.
The main advantage of Rosebud Biosciences lies in its unique approach of using patient-specific organoids to model diseases and screen drugs, potentially leading to more effective and personalized treatment options.
See something that needs updating? Suggest edits to this profile.